Survival analysis. Time to clinical response in patients treated with caplacizumab as initial treatment (n = 43∗) vs caplacizumab used in refractoriness or exacerbation (n = 32∗). (It should be noted that all patients also received PEX and corticosteroids). ∗Missing values.